Arnold & Porter

On September 1, 2024, Texas will open its new Business Court and Fifteenth Court of Appeals, offering the state’s first specialized court system for complex commercial disputes. Ryan Hartman and Andrew Bergman examine how these new courts will significantly impact the fora and decisionmakers available in complex business and other high-stakes disputes in their latest Advisory. ⬇️   #Texas #CommercialLitigation #Litigation #Business 

In a climate of heightened regulatory scrutiny, companies and the individuals at the helm now more than ever are susceptible targets of government investigations. If not handled correctly, a government investigation can put you and your company's reputation at risk, trigger civil penalties or criminal fines, and create concurrent litigation. Arnold & Porter white collar partners and veteran prosecutors Deborah Curtis, Valarie Hays, Giselle Joffre, and Meredith Osborn offer insight from their tenures, both in government and in private practice, on how to prepare for, respond to, and resolve a government investigation. Register here for the September 18 webinar ➡️ https://bit.ly/3T9e3F0 #Investigations #Disclosure #DOJ #Regulatory

Financial Services partner James Bergin was recently featured on the Fintech Takes podcast for their episode, “S8 E6: Bank Nerd Corner: What is the BSCA and What Can It Do?” Bergin, former acting co-general counsel, deputy general counsel, and chief of staff of the Federal Reserve Bank of New York, shared his insights on the Bank Service Company Act (BSCA), a law that gives bank regulators powers with respect to third-party service providers to regulated banks. Listen to the full podcast episode here ➡️ https://bit.ly/4e10MpJ #FederalReserve #Banking #Regulation #BSCA

Counsel and compliance personnel at pharmaceutical and biotech companies in the U.S. are often involved in establishing and advising European operations. The European market offers substantial opportunities for U.S. companies, but also raises complex questions for product authorization and market access — understanding and addressing these questions early in the process can prevent delays, unsuccessful launches, and later compliance problems. Join us for a unique, one-day program designed to provide U.S. lawyers with an overview of EU/UK biopharmaceutical regulation and compliance. Our European life sciences team will present an interactive program reviewing key topics relevant to the development and commercialization of medicinal products in Europe. Whether you’re new to the EU/UK regulatory frameworks for medicinal products or a veteran of the industry wanting a refresh, our Europe-based attorneys will walk you through the steps required to prepare for and execute a successful product launch. Learn firsthand from professionals who have helped companies large and small prepare to bring their products to the European market. We’ll cover the evolving framework for the regulation of medicinal products in the EU and UK, key considerations for clinical development, and strategies for commercialization. We will also provide an overview of issues relevant to medical devices used with medicinal products, EU supply chain considerations, pricing and reimbursement, EU antitrust considerations, and the new product liability regime. Register here ➡️ https://lnkd.in/e2T66t5n #Biopharma #Compliance #LifeSciences #Regulatory #ProductLaunch Jackie Mulryne | Alexander Roussanov | Adela Williams | Niels Christian Ersbøll | Ewan Townsend

I'm pleased to share my reflections in Law360 about the history and future of the Foreign Agents Registration Act's "(d)(2)" exemption, a related new FARA Unit advisory opinion with important implications for foreign-funded nonprofits, and how all of this might play into DOJ's forthcoming FARA rulemaking.

What’s Ahead for the Financial Services Industry? Key decisions from the 2023-2024 U.S. Supreme Court term are signaling a major shift in administrative law, with potential for a wave of lawsuits against the federal government. The financial services industry faces significant uncertainty around regulations and legal challenges that could lead to substantial changes. Join Arnold & Porter partners Richard M. Alexander, Veronica Callahan, John P. Elwood, and Kevin Toomey for a Practising Law Institute (PLI) webinar where they will break down the six most impactful decisions and discuss what lies ahead for the industry. Topics include: · Loper Bright Enterprises v. Raimondo · Corner Post, Inc. v. Federal Reserve · Securities and Exchange Commission v. Jarkesy · Cantero v. Bank of America, N.A. · CFPB v. Community Financial Services Association of America · Ohio et al v. Environmental Protection Agency Gain insights and prepare for the potential implications. Learn more and register ➡ https://bit.ly/4dTd8jW

Arnold & Porter advised Avantor, Inc. on a $650M agreement to divest its clinical services business to Audax Private Equity. This move supports Avantor’s ongoing business transformation, sharpening its focus on strategic growth in lab and production. The transaction is expected to close in Q4 2024. The Arnold & Porter team was led by partners Marisa White and Derek Stoldt, co-chair of the firm’s Corporate & Finance practice, and senior associates Grace S. Ansah and LaRona Mondt Kitzinger. The team also included partners Laurie Abramowitz, Tracy Belton, Henry Clinton-Davis, Debbie Feinstein, Abeba Habtemariam, Eric Rothman, and Jeremy Willcocks, senior counsel Sheryl Gittlitz, counsel Nancy L. Perkins, Ludovica Pizzetti, and Kathleen Wechter, senior associates Kathryn Geoffroy, Reuven Graber, and Emil Hristov, and associate Emelia M. Learn more ➡ https://bit.ly/3T0NTEn

Arnold & Porter was recognized as a “Leading Firm” in Chambers Latin America 2025 in three practice areas: Capital Markets, Corporate Crime & Investigations, and International Arbitration. Chambers Latin America ranks firms across 19 jurisdictions based on independent research, and this recognition highlights the firm’s excellence and reputation in the region. A special congratulations to our six lawyers that were recognized as “Leading Individuals”: · Marcus Asner—Corporate Crime & Investigations · Whitney Debevoise—Capital Markets · Paolo Di Rosa—International Arbitration · Patricio Grané Labat—International Arbitration · Greg Harrington—Banking & Finance; Capital Markets · Melida Hodgson—International Arbitration Join us in congratulating our attorneys! Read more about this recognition ➡ https://bit.ly/4dBLB6W Chambers and Partners

📜 The European Union Artificial Intelligence Act In the most recent edition of the International Comparative Legal Guide - Pharmaceutical Advertising, Jackie Mulryne, Alexander Roussanov and Christopher Bates of Arnold & Porter consider some key questions on the application of the AI Act to the life sciences industries, with a particular focus on the regulatory framework for so-called “High Risk AI Systems”, given the significant impact this will have on AI medical devices (AIMD). The full article can be accessed here 🔗 https://lnkd.in/gXaZjKw3 #LifeSciences #ArtificialIntelligence